ID   PLK1_HUMAN              Reviewed;         603 AA.
AC   P53350; Q15153; Q99746;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   05-OCT-2010, entry version 124.
DE   RecName: Full=Serine/threonine-protein kinase PLK1;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 1;
DE            Short=PLK-1;
DE   AltName: Full=Serine/threonine-protein kinase 13;
DE            Short=STPK13;
GN   Name=PLK1; Synonyms=PLK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=94289293; PubMed=8018557;
RA   Hamanaka R., Maloid S., Smith M.R., O'Connell C.D., Longo D.L.,
RA   Ferris D.K.;
RT   "Cloning and characterization of human and murine homologues of the
RT   Drosophila polo serine-threonine kinase.";
RL   Cell Growth Differ. 5:249-257(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94067140; PubMed=7902533;
RA   Lake R.J., Jelinek W.R.;
RT   "Cell cycle- and terminal differentiation-associated regulation of the
RT   mouse mRNA encoding a conserved mitotic protein kinase.";
RL   Mol. Cell. Biol. 13:7793-7801(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=95051109; PubMed=7962193;
RA   Golsteyn R.M., Schultz S.J., Bartek J., Ziemiecki A., Ried T.,
RA   Nigg E.A.;
RT   "Cell cycle analysis and chromosomal localization of human Plk1, a
RT   putative homologue of the mitotic kinases Drosophila polo and
RT   Saccharomyces cerevisiae Cdc5.";
RL   J. Cell Sci. 107:1509-1517(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   MEDLINE=94173904; PubMed=8127874; DOI=10.1073/pnas.91.5.1736;
RA   Holtrich U., Wolf G., Braeuninger A., Karn T., Boehme B.,
RA   Ruebsamen-Waigmann H., Strebhardt K.;
RT   "Induction and down-regulation of PLK, a human serine/threonine kinase
RT   expressed in proliferating cells and tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1736-1740(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=7478607;
RA   Brauninger A., Strebhardt K., Rubsamen-Waigmann H.;
RT   "Identification and functional characterization of the human and
RT   murine polo-like kinase (Plk) promoter.";
RL   Oncogene 11:1793-1800(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   MEDLINE=97238849; PubMed=9083047; DOI=10.1074/jbc.272.14.9166;
RA   Uchiumi T., Longo D.L., Ferris D.K.;
RT   "Cell cycle regulation of the human polo-like kinase (PLK) promoter.";
RL   J. Biol. Chem. 272:9166-9174(1997).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT SER-137 AND THR-210, AND MUTAGENESIS OF
RP   LYS-82; SER-137 AND THR-210.
RX   MEDLINE=22313510; PubMed=12207013; DOI=10.1074/jbc.M202172200;
RA   Jang Y.-J., Ma S., Terada Y., Erikson R.L.;
RT   "Phosphorylation of threonine 210 and the role of serine 137 in the
RT   regulation of mammalian polo-like kinase.";
RL   J. Biol. Chem. 277:44115-44120(2002).
RN   [9]
RP   PHOSPHORYLATION AT SER-335.
RX   MEDLINE=22329537; PubMed=12442251;
RX   DOI=10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y;
RA   Wind M., Kelm O., Nigg E.A., Lehmann W.D.;
RT   "Identification of phosphorylation sites in the polo-like kinases Plx1
RT   and Plk1 by a novel strategy based on element and electrospray high
RT   resolution mass spectrometry.";
RL   Proteomics 2:1516-1523(2002).
RN   [10]
RP   FUNCTION, PROTEASOMAL DEGRADATION, IDENTIFICATION OF D-BOX MOTIF, AND
RP   MUTAGENESIS OF ARG-337 AND LEU-340.
RX   PubMed=14734534; DOI=10.1083/jcb.200309035;
RA   Lindon C., Pines J.;
RT   "Ordered proteolysis in anaphase inactivates Plk1 to contribute to
RT   proper mitotic exit in human cells.";
RL   J. Cell Biol. 164:233-241(2004).
RN   [11]
RP   INTERACTION WITH CEP170.
RX   PubMed=15616186; DOI=10.1091/mbc.E04-10-0939;
RA   Guarguaglini G., Duncan P.I., Stierhof Y.D., Holmstroem T.,
RA   Duensing S., Nigg E.A.;
RT   "The forkhead-associated domain protein Cep170 interacts with Polo-
RT   like kinase 1 and serves as a marker for mature centrioles.";
RL   Mol. Biol. Cell 16:1095-1107(2005).
RN   [12]
RP   INTERACTION WITH EVI5.
RX   PubMed=16439210; DOI=10.1016/j.cell.2005.10.038;
RA   Eldridge A.G., Loktev A.V., Hansen D.V., Verschuren E.W.,
RA   Reimann J.D.R., Jackson P.K.;
RT   "The evi5 oncogene regulates cyclin accumulation by stabilizing the
RT   anaphase-promoting complex inhibitor emi1.";
RL   Cell 124:367-380(2006).
RN   [13]
RP   SUBCELLULAR LOCATION, INTERACTION WITH BUB1 AND BUB1B, AND MUTAGENESIS
RP   OF HIS-538 AND LYS-540.
RX   PubMed=16760428; DOI=10.1091/mbc.E06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [14]
RP   INTERACTION WITH ERCC6L.
RX   PubMed=17218258; DOI=10.1016/j.cell.2006.11.041;
RA   Baumann C., Koerner R., Hofmann K., Nigg E.A.;
RT   "PICH, a centromere-associated SNF2 family ATPase, is regulated by
RT   Plk1 and required for the spindle checkpoint.";
RL   Cell 128:101-114(2007).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17617734;
RA   Pouwels J., Kukkonen A.M., Lan W., Daum J.R., Gorbsky G.J.,
RA   Stukenberg T., Kallio M.J.;
RT   "Shugoshin 1 plays a central role in kinetochore assembly and is
RT   required for kinetochore targeting of Plk1.";
RL   Cell Cycle 6:1579-1585(2007).
RN   [16]
RP   INTERACTION WITH TTDN1.
RX   PubMed=17310276; DOI=10.1007/s00018-007-6501-8;
RA   Zhang Y., Tian Y., Chen Q., Chen D., Zhai Z., Shu H.-B.;
RT   "TTDN1 is a Plk1-interacting protein involved in maintenance of cell
RT   cycle integrity.";
RL   Cell. Mol. Life Sci. 64:632-640(2007).
RN   [17]
RP   INTERACTION WITH CYLD, AND MASS SPECTROMETRY.
RX   PubMed=17495026; DOI=10.1073/pnas.0703268104;
RA   Stegmeier F., Sowa M.E., Nalepa G., Gygi S.P., Harper J.W.,
RA   Elledge S.J.;
RT   "The tumor suppressor CYLD regulates entry into mitosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8869-8874(2007).
RN   [18]
RP   UBIQUITINATION BY THE APC/C COMPLEX, INTERACTION WITH FZR1, AND
RP   MUTAGENESIS OF ARG-337 AND LEU-340.
RX   PubMed=18662541; DOI=10.1016/j.cell.2008.05.043;
RA   Bassermann F., Frescas D., Guardavaccaro D., Busino L.,
RA   Peschiaroli A., Pagano M.;
RT   "The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response
RT   checkpoint.";
RL   Cell 134:256-267(2008).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PHOSPHORYLATED BORA.
RX   PubMed=18521620; DOI=10.1007/s00412-008-0165-5;
RA   Chan E.H., Santamaria A., Sillje H.H., Nigg E.A.;
RT   "Plk1 regulates mitotic Aurora A function through betaTrCP-dependent
RT   degradation of hBora.";
RL   Chromosoma 117:457-469(2008).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH SGOL1.
RX   PubMed=18331714; DOI=10.1016/j.devcel.2007.12.007;
RA   Wang X., Yang Y., Duan Q., Jiang N., Huang Y., Darzynkiewicz Z.,
RA   Dai W.;
RT   "sSgo1, a major splice variant of Sgo1, functions in centriole
RT   cohesion where it is regulated by Plk1.";
RL   Dev. Cell 14:331-341(2008).
RN   [21]
RP   INTERACTION WITH FAM29A.
RX   PubMed=19029337; DOI=10.1083/jcb.200807046;
RA   Zhu H., Coppinger J.A., Jang C.-Y., Yates J.R. III, Fang G.;
RT   "FAM29A promotes microtubule amplification via recruitment of the
RT   NEDD1-gamma-tubulin complex to the mitotic spindle.";
RL   J. Cell Biol. 183:835-848(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-6; SER-103; THR-210;
RP   THR-214; SER-375; SER-450; SER-461; THR-464 AND THR-498, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   FUNCTION, PHOSPHORYLATION AT THR-210 BY STK6/AURKA, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-82; SER-137; ASP-176 AND THR-210.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R.,
RA   Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [26]
RP   INTERACTION WITH BTBD12.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   FUNCTION, INTERACTION WITH KIF2A, AND SUBCELLULAR LOCATION.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, INTERACTION
RP   WITH CDC25C, AND MUTAGENESIS OF HIS-538 AND LYS-540.
RX   PubMed=14532005; DOI=10.1016/S0092-8674(03)00725-6;
RA   Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K.,
RA   Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B.;
RT   "The molecular basis for phosphodependent substrate targeting and
RT   regulation of Plks by the Polo-box domain.";
RL   Cell 115:83-95(2003).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE.
RX   PubMed=14592974; DOI=10.1093/emboj/cdg558;
RA   Cheng K.Y., Lowe E.D., Sinclair J., Nigg E.A., Johnson L.N.;
RT   "The crystal structure of the human polo-like kinase-1 polo box domain
RT   and its phospho-peptide complex.";
RL   EMBO J. 22:5757-5768(2003).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 13-345 OF MUTANT VAL-210 IN
RP   COMPLEXES WITH ATP ANALOGS, AND MUTAGENESIS OF THR-210.
RX   PubMed=17461553; DOI=10.1021/bi602474j;
RA   Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L.,
RA   Johnson T.L., Lewis C., Loh C., Nonomiya J., Sheils A.L.,
RA   Verdries K.A., Wynn T.A., Kuhn C., Ding Y.H.;
RT   "Structure of the catalytic domain of human polo-like kinase 1.";
RL   Biochemistry 46:5960-5971(2007).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 37-330 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR BI 2536.
RX   PubMed=18005335; DOI=10.1111/j.1747-0285.2007.00594.x;
RA   Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., Kuhn C.,
RA   Ding Y.H.;
RT   "Selectivity-determining residues in Plk1.";
RL   Chem. Biol. Drug Des. 70:540-546(2007).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 365-603 IN COMPLEX WITH
RP   CDC25C, SUBCELLULAR LOCATION, INTERACTION WITH CDC25C, ENZYME
RP   REGULATION, AND MUTAGENESIS OF TRP-414.
RX   PubMed=17307877; DOI=10.1073/pnas.0609131104;
RA   Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E.,
RA   Montoya G.;
RT   "Molecular and structural basis of polo-like kinase 1 substrate
RT   recognition: Implications in centrosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3107-3112(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-345 IN COMPLEX WITH A
RP   DARPIN.
RX   PubMed=18391401; DOI=10.1107/S0907444907068217;
RA   Bandeiras T.M., Hillig R.C., Matias P.M., Eberspaecher U.,
RA   Fanghanel J., Thomaz M., Miranda S., Crusius K., Putter V.,
RA   Amstutz P., Gulotti-Georgieva M., Binz H.K., Holz C., Schmitz A.A.,
RA   Lang C., Donner P., Egner U., Carrondo M.A., Muller-Tiemann B.;
RT   "Structure of wild-type Plk-1 kinase domain in complex with a
RT   selective DARPin.";
RL   Acta Crystallogr. D 64:339-353(2008).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 371-603 IN COMPLEX WITH
RP   PHOSPHOPEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   PHOSPHORYLATED MLF1IP.
RX   PubMed=19597481; DOI=10.1038/nsmb.1628;
RA   Yun S.M., Moulaei T., Lim D., Bang J.K., Park J.E., Shenoy S.R.,
RA   Liu F., Kang Y.H., Liao C., Soung N.K., Lee S., Yoon D.Y., Lim Y.,
RA   Lee D.H., Otaka A., Appella E., McMahon J.B., Nicklaus M.C.,
RA   Burke T.R. Jr., Yaffe M.B., Wlodawer A., Lee K.S.;
RT   "Structural and functional analyses of minimal phosphopeptides
RT   targeting the polo-box domain of polo-like kinase 1.";
RL   Nat. Struct. Mol. Biol. 16:876-882(2009).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-12; PHE-261; VAL-332; HIS-463 AND
RP   HIS-518.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that performs several
CC       important functions throughout M phase of the cell cycle,
CC       including the regulation of centrosome maturation and spindle
CC       assembly, the removal of cohesins from chromosome arms, the
CC       inactivation of APC/C inhibitors, and the regulation of mitotic
CC       exit and cytokinesis. Required for recovery after DNA damage
CC       checkpoint and entry into mitosis. Required for kinetochore
CC       localization of BUB1B. Phosphorylates SGOL1. Required for spindle
CC       pole localization of isoform 3 of SGOL1 and plays a role in
CC       regulating its centriole cohesion function. Phosphorylates BORA,
CC       and thereby promotes the degradation of BORA. Contributes to the
CC       regulation of AURKA function. Regulates TP53 stability through
CC       phosphorylation of TOPORS.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by serine and threonine
CC       phosphorylation. Once activated, activity is stimulated by binding
CC       target proteins. Binding of target proteins has no effect on the
CC       non-activated kinase.
CC   -!- SUBUNIT: Interacts with CEP170 and EVI5. Interacts and
CC       phosphorylates ERCC6L. Interacts with FAM29A. Interacts with
CC       BTBD12/SLX4 and TTDN1. Interacts with BUB1B. Interacts (via POLO-
CC       box domain) with the phosphorylated form of BUB1, MLF1IP and
CC       CDC25C. Interacts with isoform 3 of SGOL1. Interacts with BORA,
CC       KIF2A and AURKA. Interacts with TOPORS and CYLD.
CC   -!- INTERACTION:
CC       Q9NR09:BIRC6; NbExp=1; IntAct=EBI-476768, EBI-1765160;
CC       Q8IY92:BTBD12; NbExp=2; IntAct=EBI-476768, EBI-2370740;
CC       O96017:CHEK2; NbExp=3; IntAct=EBI-476768, EBI-1180783;
CC       Q2NKX8:ERCC6L; NbExp=1; IntAct=EBI-476768, EBI-1042535;
CC       O60447:EVI5; NbExp=1; IntAct=EBI-476768, EBI-852291;
CC       Q9UKT4:FBXO5; NbExp=1; IntAct=EBI-476768, EBI-852298;
CC       P49736:MCM2; NbExp=1; IntAct=EBI-476768, EBI-374819;
CC       P25205:MCM3; NbExp=1; IntAct=EBI-476768, EBI-355153;
CC       P33993:MCM7; NbExp=3; IntAct=EBI-476768, EBI-355924;
CC       P30291:WEE1; NbExp=1; IntAct=EBI-476768, EBI-914695;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere,
CC       kinetochore. Cytoplasm, cytoskeleton, centrosome. Note=During
CC       early stages of mitosis, the phosphorylated form is detected on
CC       centrosomes and kinetochores. Localizes to the outer kinetochore.
CC       Presence of SGOL1 and interaction with the phosphorylated form of
CC       BUB1 is required for the kinetochore localization.
CC   -!- TISSUE SPECIFICITY: Placenta and colon.
CC   -!- DEVELOPMENTAL STAGE: Accumulates to a maximum during the G2 and M
CC       phases, declines to a nearly undetectable level following mitosis
CC       and throughout G1 phase, and then begins to accumulate again
CC       during S phase.
CC   -!- INDUCTION: By growth-stimulating agents.
CC   -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-210.
CC       Phosphorylation at Thr-210 is first detected on centrosomes in the
CC       G2 phase of the cell cycle, peaks in prometaphase and gradually
CC       disappears from centrosomes during anaphase.
CC   -!- PTM: Autophosphorylation and phosphorylation of Ser-137 may not be
CC       significant for the activation of PLK1 during mitosis, but may
CC       enhance catalytic activity during recovery after DNA damage
CC       checkpoint.
CC   -!- PTM: Ubiquitinated by the anaphase promoting complex/cyclosome
CC       (APC/C) in anaphase and following DNA damage, leading to its
CC       degradation by the proteasome. Ubiquitination is mediated via its
CC       interaction with FZR1/CDH1. Ubiquitination and subsequent
CC       degradation prevents entry into mitosis and is essential to
CC       maintain an efficient G2 DNA damage checkpoint.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily.
CC   -!- SIMILARITY: Contains 2 POLO box domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PLK1ID41747ch16p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U01038; AAA56634.1; -; mRNA.
DR   EMBL; L19559; AAA36659.1; -; mRNA.
DR   EMBL; X73458; CAA51837.1; -; mRNA.
DR   EMBL; X75932; CAA53536.1; -; mRNA.
DR   EMBL; BC002369; AAH02369.1; -; mRNA.
DR   EMBL; BC003002; AAH03002.1; -; mRNA.
DR   EMBL; BC014846; AAH14846.1; -; mRNA.
DR   EMBL; X90725; CAA62260.1; -; Genomic_DNA.
DR   EMBL; U78073; AAB36946.1; -; Genomic_DNA.
DR   IPI; IPI00021248; -.
DR   PIR; S34130; S34130.
DR   RefSeq; NP_005021.2; -.
DR   UniGene; Hs.592049; -.
DR   PDB; 1Q4K; X-ray; 2.30 A; A/B/C=345-603.
DR   PDB; 1Q4O; X-ray; 2.20 A; A/B=367-603.
DR   PDB; 1UMW; X-ray; 1.90 A; A/B=367-603.
DR   PDB; 2OGQ; X-ray; 1.95 A; A=365-603.
DR   PDB; 2OJX; X-ray; 2.85 A; A=365-603.
DR   PDB; 2OU7; X-ray; 2.40 A; A=13-345.
DR   PDB; 2OWB; X-ray; 2.10 A; A=13-345.
DR   PDB; 2RKU; X-ray; 1.95 A; A=37-330.
DR   PDB; 2V5Q; X-ray; 2.30 A; A/B=33-345.
DR   PDB; 3BZI; X-ray; 2.10 A; A=365-603.
DR   PDB; 3C5L; X-ray; 2.33 A; A=373-593.
DR   PDB; 3FC2; X-ray; 2.45 A; A=13-345.
DR   PDB; 3FVH; X-ray; 1.58 A; A=371-603.
DR   PDB; 3HIH; X-ray; 1.70 A; A/B=371-593.
DR   PDB; 3HIK; X-ray; 1.77 A; A=367-603.
DR   PDB; 3KB7; X-ray; 2.50 A; A=36-345.
DR   PDBsum; 1Q4K; -.
DR   PDBsum; 1Q4O; -.
DR   PDBsum; 1UMW; -.
DR   PDBsum; 2OGQ; -.
DR   PDBsum; 2OJX; -.
DR   PDBsum; 2OU7; -.
DR   PDBsum; 2OWB; -.
DR   PDBsum; 2RKU; -.
DR   PDBsum; 2V5Q; -.
DR   PDBsum; 3BZI; -.
DR   PDBsum; 3C5L; -.
DR   PDBsum; 3FC2; -.
DR   PDBsum; 3FVH; -.
DR   PDBsum; 3HIH; -.
DR   PDBsum; 3HIK; -.
DR   PDBsum; 3KB7; -.
DR   ProteinModelPortal; P53350; -.
DR   DisProt; DP00428; -.
DR   DIP; DIP-29696N; -.
DR   IntAct; P53350; 67.
DR   MINT; MINT-86316; -.
DR   STRING; P53350; -.
DR   PhosphoSite; P53350; -.
DR   PRIDE; P53350; -.
DR   Ensembl; ENST00000300093; ENSP00000300093; ENSG00000166851.
DR   GeneID; 5347; -.
DR   KEGG; hsa:5347; -.
DR   UCSC; uc002dlz.1; human.
DR   CTD; 5347; -.
DR   GeneCards; GC16P023690; -.
DR   H-InvDB; HIX0012896; -.
DR   HGNC; HGNC:9077; PLK1.
DR   MIM; 602098; gene.
DR   PharmGKB; PA33410; -.
DR   eggNOG; prNOG16271; -.
DR   HOGENOM; HBG738952; -.
DR   HOVERGEN; HBG001843; -.
DR   InParanoid; P53350; -.
DR   OrthoDB; EOG9ZKN5Q; -.
DR   PhylomeDB; P53350; -.
DR   BRENDA; 2.7.11.21; 247.
DR   Pathway_Interaction_DB; foxm1pathway; FOXM1 transcription factor network.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   Reactome; REACT_383; DNA Replication.
DR   NextBio; 20722; -.
DR   ArrayExpress; P53350; -.
DR   Bgee; P53350; -.
DR   CleanEx; HS_PLK1; -.
DR   Genevestigator; P53350; -.
DR   GermOnline; ENSG00000166851; Homo sapiens.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; EXP:Reactome.
DR   GO; GO:0000942; C:outer kinetochore of condensed nuclear chro...; IDA:BHF-UCL.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042801; F:polo kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0031572; P:G2/M transition DNA damage checkpoint; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquiti...; IMP:UniProtKB.
DR   GO; GO:0051437; P:positive regulation of ubiquitin-protein li...; EXP:Reactome.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000959; POLO_box_duplicated_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR015728; Ser/Thr_prot_kinase_Polo-like.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF10; Polo-like_kinase; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division; Centromere;
KW   Chromosome; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Kinetochore; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Repeat; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN         1    603       Serine/threonine-protein kinase PLK1.
FT                                /FTId=PRO_0000086556.
FT   DOMAIN       53    305       Protein kinase.
FT   DOMAIN      417    480       POLO box 1.
FT   DOMAIN      515    584       POLO box 2.
FT   NP_BIND      59     67       ATP.
FT   NP_BIND     178    181       ATP.
FT   REGION      194    221       Activation loop.
FT   REGION      493    507       Linker.
FT   REGION      538    540       Important for interaction with
FT                                phosphorylated proteins (By similarity).
FT   MOTIF       337    340       D-box that targets the protein for
FT                                proteasomal degradation in anaphase.
FT   ACT_SITE    176    176       Proton acceptor.
FT   BINDING      82     82       ATP.
FT   BINDING     131    131       ATP; via carbonyl oxygen.
FT   BINDING     194    194       ATP.
FT   MOD_RES       6      6       Phosphothreonine.
FT   MOD_RES     103    103       Phosphoserine.
FT   MOD_RES     137    137       Phosphoserine (Probable).
FT   MOD_RES     210    210       Phosphothreonine; by STK6.
FT   MOD_RES     214    214       Phosphothreonine.
FT   MOD_RES     269    269       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     335    335       Phosphoserine.
FT   MOD_RES     375    375       Phosphoserine.
FT   MOD_RES     450    450       Phosphoserine.
FT   MOD_RES     461    461       Phosphoserine.
FT   MOD_RES     464    464       Phosphothreonine.
FT   MOD_RES     498    498       Phosphothreonine.
FT   VARIANT      12     12       R -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041018.
FT   VARIANT     261    261       L -> F (in dbSNP:rs35056440).
FT                                /FTId=VAR_041019.
FT   VARIANT     297    297       N -> D (in dbSNP:rs16972799).
FT                                /FTId=VAR_051659.
FT   VARIANT     332    332       L -> V (in dbSNP:rs45489499).
FT                                /FTId=VAR_041020.
FT   VARIANT     463    463       L -> H (in dbSNP:rs45569335).
FT                                /FTId=VAR_041021.
FT   VARIANT     518    518       R -> H (in dbSNP:rs56027600).
FT                                /FTId=VAR_041022.
FT   VARIANT     595    595       S -> L (in dbSNP:rs34001032).
FT                                /FTId=VAR_051660.
FT   VARIANT     599    599       R -> H (in dbSNP:rs34954545).
FT                                /FTId=VAR_051661.
FT   MUTAGEN      82     82       K->M,R: Abolishes activity.
FT   MUTAGEN     137    137       S->A: No change in activity. Increases
FT                                activity and restores recovery after DNA
FT                                damage checkpoint; when associated with
FT                                D-210.
FT   MUTAGEN     137    137       S->D: Increases activity. Results in a
FT                                block in G1/S.
FT   MUTAGEN     176    176       D->N: Abolishes kinase activity.
FT   MUTAGEN     210    210       T->A: Abolishes activity. Abolishes
FT                                checkpoint recovery.
FT   MUTAGEN     210    210       T->D: Increases activity and restores
FT                                recovery after DNA damage checkpoint.
FT   MUTAGEN     210    210       T->V: Reduced catalytic activity, but no
FT                                effect on affinity for ATP.
FT   MUTAGEN     337    337       R->A: Interferes with ubiquitination and
FT                                subsequent proteasomal degradation in
FT                                anaphase; when associated with A-340.
FT   MUTAGEN     340    340       L->A: Interferes with ubiquitination and
FT                                subsequent proteasomal degradation in
FT                                anaphase; when associated with A-337.
FT   MUTAGEN     414    414       W->F: Abolishes interaction with CDC25C
FT                                and reduces centrosomal localization.
FT   MUTAGEN     538    538       H->A: Loss of centrosomal location and
FT                                decreased interaction with phosphorylated
FT                                CDC25C and BUB1; when associated with M-
FT                                540.
FT   MUTAGEN     540    540       K->M: Loss of centrosomal location and
FT                                decreased interaction with phosphorylated
FT                                CDC25C and BUB1; when associated with A-
FT                                538.
FT   CONFLICT      2      2       S -> T (in Ref. 1; AAA56634).
FT   CONFLICT     11     11       A -> P (in Ref. 1; AAA56634).
FT   CONFLICT     58     58       F -> L (in Ref. 1; AAA56634).
FT   CONFLICT     60     60       G -> S (in Ref. 1; AAA56634).
FT   CONFLICT     73     73       A -> V (in Ref. 2; AAA36659 and 7;
FT                                AAB36946).
FT   CONFLICT    123    123       N -> T (in Ref. 6; CAA62260).
FT   CONFLICT    141    141       L -> P (in Ref. 4; CAA53536).
FT   CONFLICT    227    227       G -> E (in Ref. 4; CAA53536).
FT   CONFLICT    301    301       N -> G (in Ref. 2; AAA36659).
FT   CONFLICT    495    495       A -> G (in Ref. 2; AAA36659).
FT   CONFLICT    501    501       E -> Q (in Ref. 2; AAA36659).
FT   STRAND       42     46
FT   TURN         47     50
FT   STRAND       51     62
FT   STRAND       65     72
FT   TURN         73     75
FT   STRAND       78     85
FT   HELIX        86     88
FT   HELIX        92    106
FT   STRAND      116    121
FT   STRAND      123    130
FT   HELIX       138    145
FT   HELIX       150    169
FT   HELIX       179    181
FT   STRAND      182    184
FT   STRAND      190    192
FT   HELIX       220    223
FT   HELIX       231    246
FT   HELIX       256    265
FT   HELIX       276    285
FT   HELIX       290    292
FT   TURN        296    298
FT   HELIX       299    301
FT   HELIX       303    306
FT   HELIX       316    319
FT   HELIX       373    386
FT   STRAND      391    394
FT   HELIX       397    400
FT   HELIX       403    405
FT   STRAND      411    416
FT   TURN        418    420
FT   STRAND      421    427
FT   STRAND      432    436
FT   STRAND      441    444
FT   STRAND      448    454
FT   STRAND      460    465
FT   HELIX       470    472
FT   HELIX       473    489
FT   TURN        493    496
FT   STRAND      511    516
FT   STRAND      518    525
FT   STRAND      530    534
FT   TURN        535    537
FT   STRAND      540    544
FT   TURN        545    548
FT   STRAND      549    553
FT   STRAND      559    563
FT   HELIX       564    570
FT   HELIX       574    592
SQ   SEQUENCE   603 AA;  68255 MW;  178C2F13C10E8206 CRC64;
     MSAAVTAGKL ARAPADPGKA GVPGVAAPGA PAAAPPAKEI PEVLVDPRSR RRYVRGRFLG
     KGGFAKCFEI SDADTKEVFA GKIVPKSLLL KPHQREKMSM EISIHRSLAH QHVVGFHGFF
     EDNDFVFVVL ELCRRRSLLE LHKRRKALTE PEARYYLRQI VLGCQYLHRN RVIHRDLKLG
     NLFLNEDLEV KIGDFGLATK VEYDGERKKT LCGTPNYIAP EVLSKKGHSF EVDVWSIGCI
     MYTLLVGKPP FETSCLKETY LRIKKNEYSI PKHINPVAAS LIQKMLQTDP TARPTINELL
     NDEFFTSGYI PARLPITCLT IPPRFSIAPS SLDPSNRKPL TVLNKGLENP LPERPREKEE
     PVVRETGEVV DCHLSDMLQQ LHSVNASKPS ERGLVRQEEA EDPACIPIFW VSKWVDYSDK
     YGLGYQLCDN SVGVLFNDST RLILYNDGDS LQYIERDGTE SYLTVSSHPN SLMKKITLLK
     YFRNYMSEHL LKAGANITPR EGDELARLPY LRTWFRTRSA IILHLSNGSV QINFFQDHTK
     LILCPLMAAV TYIDEKRDFR TYRLSLLEEY GCCKELASRL RYARTMVDKL LSSRSASNRL
     KAS
//
